Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela Dispenzieri

Showing results (391-400 of 759) with videos related to

Pageof 76
Sort By:
Clinical Chemistry and Laboratory Medicine|September 25, 2023
Amino acid sequence homology of monoclonal serum free light chain dimers and tissue deposited light chains in AL amyloidosis: a pilot studyRivka Goldis, Batia Kaplan, Michael Arad, et al.
American Journal of Hematology|September 28, 2010
Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugsAngela Dispenzieri, David Dingli, Shaji K Kumar, et al.
Mayo Clinic Proceedings|January 17, 2003
Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myelomaShaji Kumar, Morie A Gertz, Angela Dispenzieri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosisS Vincent Rajkumar, Ruben A Mesa, Rafael Fonseca, et al.
Blood|May 28, 2017
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosisVaishali Sanchorawala, Giovanni Palladini, Vishal Kukreti, et al.
British Journal of Haematology|May 1, 2018
Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantationRajshekhar Chakraborty, Eli Muchtar, Shaji K Kumar, et al.
American Journal of Hematology|November 15, 2011
Acute kidney injury during leukocyte engraftment after autologous stem cell transplantation in patients with light-chain amyloidosisMaria V Irazabal, Alfonso Eirin, Morie A Gertz, et al.
Blood Advances|March 22, 2022
Prevalence of heavy chain MGUS by race and family history risk groups using a high-sensitivity screening methodCeline M Vachon, Josiah Murray, Cristine Allmer, et al.
Blood|September 25, 2024
Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysisRahul Banerjee, Rachael Sexton, Andrew J Cowan, et al.
American Journal of Hematology|August 24, 2010
Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myelomaKristen Detweiler-Short, Suzanne Hayman, Morie A Gertz, et al.
Pageof 76

Showing results (391-400 of 759) with videos related to

Sort By:
Pageof 76
Clinical Chemistry and Laboratory Medicine|September 25, 2023
Amino acid sequence homology of monoclonal serum free light chain dimers and tissue deposited light chains in AL amyloidosis: a pilot studyRivka Goldis, Batia Kaplan, Michael Arad, et al.
American Journal of Hematology|September 28, 2010
Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugsAngela Dispenzieri, David Dingli, Shaji K Kumar, et al.
Mayo Clinic Proceedings|January 17, 2003
Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myelomaShaji Kumar, Morie A Gertz, Angela Dispenzieri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosisS Vincent Rajkumar, Ruben A Mesa, Rafael Fonseca, et al.
Blood|May 28, 2017
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosisVaishali Sanchorawala, Giovanni Palladini, Vishal Kukreti, et al.
British Journal of Haematology|May 1, 2018
Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantationRajshekhar Chakraborty, Eli Muchtar, Shaji K Kumar, et al.
American Journal of Hematology|November 15, 2011
Acute kidney injury during leukocyte engraftment after autologous stem cell transplantation in patients with light-chain amyloidosisMaria V Irazabal, Alfonso Eirin, Morie A Gertz, et al.
Blood Advances|March 22, 2022
Prevalence of heavy chain MGUS by race and family history risk groups using a high-sensitivity screening methodCeline M Vachon, Josiah Murray, Cristine Allmer, et al.
Blood|September 25, 2024
Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysisRahul Banerjee, Rachael Sexton, Andrew J Cowan, et al.
American Journal of Hematology|August 24, 2010
Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myelomaKristen Detweiler-Short, Suzanne Hayman, Morie A Gertz, et al.
Pageof 76